Microflow UPLC and high-resolution MS as a sensitive and robust platform for quantitation of intact peptide hormones

被引：13

作者：

Chen, Zhuo ^{[1
]}

Alelyunas, Yun W. ^{[2
]}

Wrona, Mark D. ^{[2
]}

Kehler, Jonathan R. ^{[3
]}

Szapacs, Matthew E. ^{[1
]}

Evans, Christopher A. ^{[1
]}

机构：

[1] GlaxoSmithKline, R&D Res, Invitro In Vivo Translat, Exploratory Biomarker Assay, 1250 South Collegeville Rd, Collegeville, PA 19426 USA

[2] Waters Corp, Sci Operat, 34 Maple St, Milford, MA 01757 USA

[3] GlaxoSmithKline, R&D Res, In Vitro In Vivo Translat, Bioanal, 1250 South Collegeville Rd, Collegeville, PA 19426 USA

来源：

BIOANALYSIS | 2019年 / 11卷 / 13期

关键词：

HRMS; large molecules; microflow-UPLC; TOF-MRM; MASS-SPECTROMETRY; LIQUID-CHROMATOGRAPHY; LC-MS/MS; QUANTIFICATION; PLASMA; ASSAYS;

D O I：

10.4155/bio-2019-0081

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Aim: Recent advances in microflow ultra performance liquid chromatography (UPLC) systems offer higher sensitivity with robustness to meet the routine bioanalytical demands. Modern high-resolution mass spectrometers (HRMS) enable the development of highly selective methods with broad dynamic range. Results: The quantitative performances of tandem quadrupole MS and HRMS were comprehensively compared using seven intact peptide hormones up to 9.4 kDa. Results show comparable performance between two platforms in sensitivity, accuracy and linearity. For some peptides, HRMS provided lower background interference. The benefit of increased sensitivity using microflow UPLC was also demonstrated. Conclusion: HRMS is a versatile platform capable of both basic characterization and reliable quantitation in complex matrices. Microflow UPLC provides lower LLOQs than conventional flow systems, even with less sample volume injected.

引用

页码：1275 / 1289

页数：15

共 28 条

[1] Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins
Anderson, L
Hunter, CL
[J]. MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (04) : 573 - 588
[2] Arnold DW, 2013, BIOANALYSIS, V5, P1329, DOI [10.4155/BIO.13.31, 10.4155/bio.13.31]
[3] Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Borrebaeck, Carl A. K.
[J]. NATURE REVIEWS CANCER, 2017, 17 (03) : 199 - 204
[4] Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses
Chambers, Erin
Wagrowski-Diehl, Diane M.
Lu, Ziling
Mazzeo, Jeffrey R.
[J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2): : 22 - 34
[5] Advances in mass spectrometry-based clinical biomarker discovery
Crutchfield, Christopher A.
Thomas, Stefani N.
Sokoll, Lori J.
Chan, Daniel W.
[J]. CLINICAL PROTEOMICS, 2016, 13
[6] Dillen L, 2013, BIOANALYSIS, V5, P1145, DOI [10.4155/BIO.13.90, 10.4155/bio.13.90]
[7] The application of a new microfluidic device for the simultaneous identification and quantitation of midazolam metabolites obtained from a single micro-litre of chimeric mice blood
Gallagher, Richard
Dillon, Leonard
Grimsley, Aidan
Murphy, Jim
Samuelsson, Kristin
Douce, David
[J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2014, 28 (11) : 1293 - 1302
[8] The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry
Hoofnagle, Andrew N.
Wener, Mark H.
[J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 347 (1-2) : 3 - 11
[9] Application of high-resolution MS for development of peptide and large-molecule drug candidates
Kellie, John F.
Kehler, Jonathan R.
Szapacs, Matthew E.
[J]. BIOANALYSIS, 2016, 8 (03) : 169 - 177
[10] Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution
Keshishian, Hasmik
Addona, Terri
Burgess, Michael
Kuhn, Eric
Carr, Steven A.
[J]. MOLECULAR & CELLULAR PROTEOMICS, 2007, 6 (12) : 2212 - 2229

← 1 2 3 →